التفاصيل البيبلوغرافية
| العنوان: |
ZUMA‐23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST‐LINE THERAPY IN PATIENTS WITH HIGH‐RISK LARGE B‐CELL LYMPHOMA. |
| المؤلفون: |
Westin, J., Jacobson, C. A., Chavez, J. C., Sureda, A., Morschhauser, F., Glaß, B., Dickinson, M., Davies, A., Flinn, I. W., Maloney, D. G., Chamuleau, M., Tees, M., Xue, A., Shahani, S., Nikolajeva, O., Kang, J., Kaplan, A., Schupp, M., Miao, H., Rich, E. S. |
| المصدر: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p171-173, 3p |
| مصطلحات موضوعية: |
DIFFUSE large B-cell lymphomas, NURSING consultants, MUCOSA-associated lymphoid tissue lymphoma, LYMPHOMAS, CYTOKINE release syndrome |
| مستخلص: |
B Methods: b The Phase 3 trial design will enroll 300 adult patients with high-risk, histologically confirmed LBCL based on the 2016 WHO classification, including diffuse large B-cell lymphoma, HGBL, and transformed follicular or marginal zone lymphoma (Swerdlow SH, et al. I Blood i . 2016). B Introduction: b The nearly 40% of patients with large B-cell lymphoma (LBCL) who are refractory to or relapse after current first-line standard-of-care (SOC) regimens, such as R-CHOP (rituximab [R] + cyclophosphamide [C], doxorubicin [H], vincristine [O], and prednisone [P]) and DA-EPOCH-R (dose-adjusted etoposide [DA-E]), have poor prognoses. ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA. [Extracted from the article] |
|
Copyright of Hematological Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder